Drugs / BLU-945
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04862780 | Jun 2021 → Oct 2024 | adenocarcinoma, bronchogenic carcinoma, non-small cell lung carcinoma | Blueprint Medicines Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLU-945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04862780 ↗ |
| Action | Inhibit | “BLU-945, a selective EGFR inhibitor” NCT04862780 ↗ |
| Target | EGFR | “BLU-945, a selective EGFR inhibitor” NCT04862780 ↗ |